Sugi Predict

Sugi Predict / Compounds / SCHEMBL2525507

SCHEMBL2525507

SCHEMBL2525507

CCOC1CCN(c2ccc(Nc3ncc(F)c(Nc4ccc5c(n4)NC(=O)C(C)(C)O5)n3)cn2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 12/20 0.57
▸ EGFR P00533 6/20 0.57
▸ LRRK2 Q5S007 3/20 0.57
▸ BTK Q06187 3/20 0.57
▸ ADORA3 P0DMS8 2/20 0.57
▸ TYRO3 Q06418 2/20 0.57
▸ PLK4 O00444 2/20 0.57
▸ AURKA O14965 2/20 0.57
▸ STK16 O75716 2/20 0.57
▸ RET P07949 2/20 0.57
▸ FLT3 P36888 2/20 0.57
▸ MAPK8 P45983 2/20 0.57
▸ MAPK9 P45984 2/20 0.57
▸ MST1R Q04912 2/20 0.57
▸ PTK2 Q05397 2/20 0.57
▸ TNK1 Q13470 2/20 0.57
▸ IKBKE Q14164 2/20 0.57
▸ MAP3K11 Q16584 2/20 0.57
▸ ADCK1 Q86TW2 2/20 0.57
▸ PIP4K2C Q8TBX8 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12213007 0.96 SYK (0.56) SYKEGFRLRRK2BTKADORA3
SCHEMBL2522493 0.96 SYK (0.56) SYKEGFRLRRK2BTKADORA3
SCHEMBL2520950 0.92 SYK (0.61) SYKEGFRLRRK2BTKADORA3
SCHEMBL2523840 0.91 SYK (0.59) SYKEGFRLRRK2BTKADORA3
SCHEMBL12213004 0.89 SYK (0.60) SYKEGFRLRRK2BTKADORA3
SCHEMBL2522011 0.89 SYK (0.60) SYKEGFRLRRK2BTKADORA3
SCHEMBL2525494 0.89 SYK (0.59) SYKEGFRLRRK2BTKADORA3
SCHEMBL2523184 0.89 SYK (0.55) SYKEGFRLRRK2BTKADORA3
SCHEMBL12213131 0.88 SYK (0.59) SYKEGFRLRRK2BTKADORA3
SCHEMBL12621080 0.87 SYK (0.62) SYKEGFRLRRK2BTKADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2558474-B1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS INC (US) 2015-11-25 — — EP claimed
US-8618095-B2 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses RIGEL PHARMACEUTICALS, INC. (US) 2013-12-31 — — US claimed
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2011-10-13 — — US claimed
EP-2558474-B1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS INC (US) 2015-11-25 — — EP disclosed
US-8618095-B2 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses RIGEL PHARMACEUTICALS, INC. (US) 2013-12-31 — — US disclosed
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2011-10-13 — — US disclosed
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2011-10-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES TYMP, DPYD, TYMS SYK 1871/4885EGFR 3393/4885LRRK2 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.